Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC trimmed its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 2.7% in the first quarter, Holdings Channel.com reports. The fund owned 42,119 shares of the biopharmaceutical company’s stock after selling 1,151 shares during the period. Yousif Capital Management LLC’s holdings in Catalyst Pharmaceuticals were worth $1,021,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of Catalyst Pharmaceuticals by 4.9% during the 4th quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company’s stock valued at $175,957,000 after acquiring an additional 390,116 shares during the period. Renaissance Technologies LLC raised its position in shares of Catalyst Pharmaceuticals by 7.1% during the 4th quarter. Renaissance Technologies LLC now owns 2,706,116 shares of the biopharmaceutical company’s stock worth $56,477,000 after purchasing an additional 180,100 shares during the last quarter. Castlekeep Investment Advisors LLC acquired a new position in shares of Catalyst Pharmaceuticals during the 4th quarter worth approximately $37,494,000. Bank of America Corp DE raised its position in shares of Catalyst Pharmaceuticals by 139.5% during the 4th quarter. Bank of America Corp DE now owns 1,568,791 shares of the biopharmaceutical company’s stock worth $32,741,000 after purchasing an additional 913,843 shares during the last quarter. Finally, Northern Trust Corp raised its position in shares of Catalyst Pharmaceuticals by 8.7% during the 4th quarter. Northern Trust Corp now owns 1,503,566 shares of the biopharmaceutical company’s stock worth $31,379,000 after purchasing an additional 119,766 shares during the last quarter. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Preethi Sundaram sold 1,600 shares of the business’s stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total transaction of $42,272.00. Following the completion of the sale, the insider now directly owns 41,081 shares of the company’s stock, valued at $1,085,360.02. The trade was a 3.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Gary Ingenito sold 44,000 shares of the business’s stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $23.63, for a total transaction of $1,039,720.00. Following the sale, the insider now directly owns 68,873 shares of the company’s stock, valued at $1,627,468.99. This represents a 38.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 247,924 shares of company stock valued at $5,879,369. Company insiders own 10.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, June 5th. Wall Street Zen upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 28th. HC Wainwright restated a “buy” rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Stephens restated an “overweight” rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Finally, Robert W. Baird lifted their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research report on Monday, March 3rd. Six analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, Catalyst Pharmaceuticals currently has an average rating of “Buy” and an average target price of $32.83.

Catalyst Pharmaceuticals Stock Performance

CPRX stock opened at $22.81 on Thursday. The stock has a market capitalization of $2.78 billion, a P/E ratio of 14.53, a PEG ratio of 0.95 and a beta of 0.72. Catalyst Pharmaceuticals, Inc. has a one year low of $14.75 and a one year high of $26.58. The company has a 50 day moving average price of $23.91 and a two-hundred day moving average price of $22.89.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.